Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;10(5):801. doi: 10.3390/vaccines10050801

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Cytotoxic marker levels. (Panel A) Patients included in this analysis were treated with mycophenolate mofetil (MFM, n = 2) at 3 g/day, baricitinib (BARI, n = 3) at 4 mg/day, and adalimumab (ADA, n = 3) at 40 mg/2 weeks. The patients and controls (ctrl, n = 4) were all COVID-naïve. (Panel B) Patients (n = 8) were compared based on MFM treatment, seroconversion status (Ab+ = seroconverted, Ab- = not seroconverted), and previous history of COVID-19 (previous COVID-19= ex-C or COVID-naïve=-naïve). Each black spot represents a patient, the bars indicate means and standard errors of the mean (SEM) of the marker levels.